Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study

Apixaban and rivaroxaban require lead-in dosing for 7 and 21 days, respectively, when treating venous thromboembolism (VTE). However, no evidence exists to support subtracting parenteral anticoagulation days from total lead-in dosing. A multicenter study was conducted, including adult patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshaya, Omar A., Korayem, Ghazwa B., Al Yami, Majed S., Qudayr, Asma H., Althewaibi, Sara, Fetyani, Lolwa, Alshehri, Shaden, Alnashmi, Fai, Albasseet, Maram, Alshehri, Lina, Alhushan, Lina M., Almohammed, Omar A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821121/
https://www.ncbi.nlm.nih.gov/pubmed/36615002
http://dx.doi.org/10.3390/jcm12010199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821121/
https://www.ncbi.nlm.nih.gov/pubmed/36615002
http://dx.doi.org/10.3390/jcm12010199

Ejemplares similares